.jpg)
Apollomics hands Asia rights to its lead c-MET inhibitor to Taiwan’s LaunXP in $60M deal
Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical for $10 million upfront.
Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical for $10 million upfront.
